CA2086342A1 - Methode permettant d'introduire un peptide dans un cytosol - Google Patents
Methode permettant d'introduire un peptide dans un cytosolInfo
- Publication number
- CA2086342A1 CA2086342A1 CA002086342A CA2086342A CA2086342A1 CA 2086342 A1 CA2086342 A1 CA 2086342A1 CA 002086342 A CA002086342 A CA 002086342A CA 2086342 A CA2086342 A CA 2086342A CA 2086342 A1 CA2086342 A1 CA 2086342A1
- Authority
- CA
- Canada
- Prior art keywords
- toxin
- cytosol
- peptide
- mutant
- cells
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Abandoned
Links
- 108090000765 processed proteins & peptides Proteins 0.000 title claims abstract description 28
- 210000000172 cytosol Anatomy 0.000 title claims abstract description 26
- 238000000034 method Methods 0.000 title claims abstract description 16
- 210000004027 cell Anatomy 0.000 claims abstract description 42
- 229960005486 vaccine Drugs 0.000 claims abstract description 11
- 239000000427 antigen Substances 0.000 claims abstract description 10
- 108091007433 antigens Proteins 0.000 claims abstract description 10
- 102000036639 antigens Human genes 0.000 claims abstract description 10
- 241000700605 Viruses Species 0.000 claims abstract description 9
- 231100000699 Bacterial toxin Toxicity 0.000 claims abstract description 8
- 231100000742 Plant toxin Toxicity 0.000 claims abstract description 8
- 230000001580 bacterial effect Effects 0.000 claims abstract description 8
- 239000000688 bacterial toxin Substances 0.000 claims abstract description 8
- 239000003123 plant toxin Substances 0.000 claims abstract description 8
- 241000894006 Bacteria Species 0.000 claims abstract description 5
- 102000008949 Histocompatibility Antigens Class I Human genes 0.000 claims abstract description 5
- 108010088652 Histocompatibility Antigens Class I Proteins 0.000 claims abstract description 5
- 244000045947 parasite Species 0.000 claims abstract description 4
- 206010028980 Neoplasm Diseases 0.000 claims abstract description 3
- 210000001744 T-lymphocyte Anatomy 0.000 claims abstract description 3
- 230000028993 immune response Effects 0.000 claims abstract description 3
- 230000003834 intracellular effect Effects 0.000 claims abstract description 3
- 230000036210 malignancy Effects 0.000 claims abstract description 3
- 231100000765 toxin Toxicity 0.000 claims description 28
- 239000003053 toxin Substances 0.000 claims description 26
- 108010053187 Diphtheria Toxin Proteins 0.000 claims description 11
- 102000004196 processed proteins & peptides Human genes 0.000 claims description 11
- 102000016607 Diphtheria Toxin Human genes 0.000 claims description 10
- 239000000463 material Substances 0.000 claims description 9
- 231100000252 nontoxic Toxicity 0.000 claims description 4
- 230000003000 nontoxic effect Effects 0.000 claims description 4
- 108010066676 Abrin Proteins 0.000 claims description 2
- 108010049048 Cholera Toxin Proteins 0.000 claims description 2
- 102000009016 Cholera Toxin Human genes 0.000 claims description 2
- 108010081690 Pertussis Toxin Proteins 0.000 claims description 2
- 108010039491 Ricin Proteins 0.000 claims description 2
- 108010079723 Shiga Toxin Proteins 0.000 claims description 2
- 108010022050 mistletoe lectin I Proteins 0.000 claims description 2
- 108010010621 modeccin Proteins 0.000 claims description 2
- 231100000419 toxicity Toxicity 0.000 claims description 2
- 230000001988 toxicity Effects 0.000 claims description 2
- 241000588724 Escherichia coli Species 0.000 claims 1
- 101900161471 Pseudomonas aeruginosa Exotoxin A Proteins 0.000 claims 1
- 230000002311 subsequent effect Effects 0.000 claims 1
- 108010043904 volkensin Proteins 0.000 claims 1
- KQNNSYZQMSOOQH-GLDAUDTLSA-N volkensin Chemical compound C=1([C@@H]2C[C@@H]3O[C@@H](O)C[C@@H]4[C@]5(C)[C@H]6[C@H]([C@H]([C@@]4(C)C3=C2C)O)OC[C@]6(C)[C@H](OC(C)=O)C[C@@H]5OC(=O)C(/C)=C/C)C=COC=1 KQNNSYZQMSOOQH-GLDAUDTLSA-N 0.000 claims 1
- 239000012634 fragment Substances 0.000 description 30
- 108700012359 toxins Proteins 0.000 description 25
- 108090000623 proteins and genes Proteins 0.000 description 10
- 230000014616 translation Effects 0.000 description 10
- 238000013519 translation Methods 0.000 description 9
- JKMHFZQWWAIEOD-UHFFFAOYSA-N 2-[4-(2-hydroxyethyl)piperazin-1-yl]ethanesulfonic acid Chemical compound OCC[NH+]1CCN(CCS([O-])(=O)=O)CC1 JKMHFZQWWAIEOD-UHFFFAOYSA-N 0.000 description 8
- 239000000047 product Substances 0.000 description 8
- 235000018102 proteins Nutrition 0.000 description 8
- 102000004169 proteins and genes Human genes 0.000 description 8
- 108010059712 Pronase Proteins 0.000 description 7
- 108010076504 Protein Sorting Signals Proteins 0.000 description 7
- 239000012528 membrane Substances 0.000 description 7
- 108010038807 Oligopeptides Proteins 0.000 description 6
- 102000015636 Oligopeptides Human genes 0.000 description 6
- 239000001397 quillaja saponaria molina bark Substances 0.000 description 6
- 229930182490 saponin Natural products 0.000 description 6
- 150000007949 saponins Chemical class 0.000 description 6
- 230000000875 corresponding effect Effects 0.000 description 5
- YBYRMVIVWMBXKQ-UHFFFAOYSA-N phenylmethanesulfonyl fluoride Chemical compound FS(=O)(=O)CC1=CC=CC=C1 YBYRMVIVWMBXKQ-UHFFFAOYSA-N 0.000 description 5
- GHAZCVNUKKZTLG-UHFFFAOYSA-N N-ethyl-succinimide Natural products CCN1C(=O)CCC1=O GHAZCVNUKKZTLG-UHFFFAOYSA-N 0.000 description 4
- HDFGOPSGAURCEO-UHFFFAOYSA-N N-ethylmaleimide Chemical compound CCN1C(=O)C=CC1=O HDFGOPSGAURCEO-UHFFFAOYSA-N 0.000 description 4
- 108090000631 Trypsin Proteins 0.000 description 4
- 102000004142 Trypsin Human genes 0.000 description 4
- 206010013023 diphtheria Diseases 0.000 description 4
- 238000000338 in vitro Methods 0.000 description 4
- 229920001184 polypeptide Polymers 0.000 description 4
- 210000002966 serum Anatomy 0.000 description 4
- 238000002415 sodium dodecyl sulfate polyacrylamide gel electrophoresis Methods 0.000 description 4
- 230000005945 translocation Effects 0.000 description 4
- 239000012588 trypsin Substances 0.000 description 4
- 101000663658 Aptenodytes patagonicus Spheniscin-1 Proteins 0.000 description 3
- 229930191564 Monensin Natural products 0.000 description 3
- GAOZTHIDHYLHMS-UHFFFAOYSA-N Monensin A Natural products O1C(CC)(C2C(CC(O2)C2C(CC(C)C(O)(CO)O2)C)C)CCC1C(O1)(C)CCC21CC(O)C(C)C(C(C)C(OC)C(C)C(O)=O)O2 GAOZTHIDHYLHMS-UHFFFAOYSA-N 0.000 description 3
- 230000000890 antigenic effect Effects 0.000 description 3
- 230000002238 attenuated effect Effects 0.000 description 3
- 210000001151 cytotoxic T lymphocyte Anatomy 0.000 description 3
- 230000003211 malignant effect Effects 0.000 description 3
- 230000007246 mechanism Effects 0.000 description 3
- 229960005358 monensin Drugs 0.000 description 3
- GAOZTHIDHYLHMS-KEOBGNEYSA-N monensin A Chemical compound C([C@@](O1)(C)[C@H]2CC[C@@](O2)(CC)[C@H]2[C@H](C[C@@H](O2)[C@@H]2[C@H](C[C@@H](C)[C@](O)(CO)O2)C)C)C[C@@]21C[C@H](O)[C@@H](C)[C@@H]([C@@H](C)[C@@H](OC)[C@H](C)C(O)=O)O2 GAOZTHIDHYLHMS-KEOBGNEYSA-N 0.000 description 3
- 239000002953 phosphate buffered saline Substances 0.000 description 3
- 239000012134 supernatant fraction Substances 0.000 description 3
- BWGNESOTFCXPMA-UHFFFAOYSA-N Dihydrogen disulfide Chemical compound SS BWGNESOTFCXPMA-UHFFFAOYSA-N 0.000 description 2
- 102000004190 Enzymes Human genes 0.000 description 2
- 108090000790 Enzymes Proteins 0.000 description 2
- FFEARJCKVFRZRR-BYPYZUCNSA-N L-methionine Chemical compound CSCC[C@H](N)C(O)=O FFEARJCKVFRZRR-BYPYZUCNSA-N 0.000 description 2
- 102000043129 MHC class I family Human genes 0.000 description 2
- 108091054437 MHC class I family Proteins 0.000 description 2
- MQUQNUAYKLCRME-INIZCTEOSA-N N-tosyl-L-phenylalanyl chloromethyl ketone Chemical compound C1=CC(C)=CC=C1S(=O)(=O)N[C@H](C(=O)CCl)CC1=CC=CC=C1 MQUQNUAYKLCRME-INIZCTEOSA-N 0.000 description 2
- 241000283973 Oryctolagus cuniculus Species 0.000 description 2
- 229920002684 Sepharose Polymers 0.000 description 2
- FAPWRFPIFSIZLT-UHFFFAOYSA-M Sodium chloride Chemical compound [Na+].[Cl-] FAPWRFPIFSIZLT-UHFFFAOYSA-M 0.000 description 2
- 230000002378 acidificating effect Effects 0.000 description 2
- 229940024606 amino acid Drugs 0.000 description 2
- 235000001014 amino acid Nutrition 0.000 description 2
- 150000001413 amino acids Chemical group 0.000 description 2
- 230000030741 antigen processing and presentation Effects 0.000 description 2
- 238000005119 centrifugation Methods 0.000 description 2
- 230000008030 elimination Effects 0.000 description 2
- 238000003379 elimination reaction Methods 0.000 description 2
- 238000002474 experimental method Methods 0.000 description 2
- 230000035772 mutation Effects 0.000 description 2
- 239000008188 pellet Substances 0.000 description 2
- 239000013612 plasmid Substances 0.000 description 2
- 238000002264 polyacrylamide gel electrophoresis Methods 0.000 description 2
- YNJBWRMUSHSURL-UHFFFAOYSA-N trichloroacetic acid Chemical compound OC(=O)C(Cl)(Cl)Cl YNJBWRMUSHSURL-UHFFFAOYSA-N 0.000 description 2
- GPRLSGONYQIRFK-MNYXATJNSA-N triton Chemical compound [3H+] GPRLSGONYQIRFK-MNYXATJNSA-N 0.000 description 2
- 210000003501 vero cell Anatomy 0.000 description 2
- 230000005730 ADP ribosylation Effects 0.000 description 1
- BVKZGUZCCUSVTD-UHFFFAOYSA-M Bicarbonate Chemical compound OC([O-])=O BVKZGUZCCUSVTD-UHFFFAOYSA-M 0.000 description 1
- 108010001857 Cell Surface Receptors Proteins 0.000 description 1
- 108091026890 Coding region Proteins 0.000 description 1
- 102100031334 Elongation factor 2 Human genes 0.000 description 1
- 101710082714 Exotoxin A Proteins 0.000 description 1
- 108091034117 Oligonucleotide Proteins 0.000 description 1
- 229910019142 PO4 Inorganic materials 0.000 description 1
- 108010077519 Peptide Elongation Factor 2 Proteins 0.000 description 1
- 241000589516 Pseudomonas Species 0.000 description 1
- 108010065868 RNA polymerase SP6 Proteins 0.000 description 1
- DBMJMQXJHONAFJ-UHFFFAOYSA-M Sodium laurylsulphate Chemical compound [Na+].CCCCCCCCCCCCOS([O-])(=O)=O DBMJMQXJHONAFJ-UHFFFAOYSA-M 0.000 description 1
- 241000473945 Theria <moth genus> Species 0.000 description 1
- 238000013459 approach Methods 0.000 description 1
- 108010028263 bacteriophage T3 RNA polymerase Proteins 0.000 description 1
- 230000003139 buffering effect Effects 0.000 description 1
- 239000003638 chemical reducing agent Substances 0.000 description 1
- 230000001086 cytosolic effect Effects 0.000 description 1
- 231100000433 cytotoxic Toxicity 0.000 description 1
- 230000001472 cytotoxic effect Effects 0.000 description 1
- 230000002939 deleterious effect Effects 0.000 description 1
- LOKCTEFSRHRXRJ-UHFFFAOYSA-I dipotassium trisodium dihydrogen phosphate hydrogen phosphate dichloride Chemical compound P(=O)(O)(O)[O-].[K+].P(=O)(O)([O-])[O-].[Na+].[Na+].[Cl-].[K+].[Cl-].[Na+] LOKCTEFSRHRXRJ-UHFFFAOYSA-I 0.000 description 1
- 230000000694 effects Effects 0.000 description 1
- 210000001163 endosome Anatomy 0.000 description 1
- 238000006911 enzymatic reaction Methods 0.000 description 1
- 229940050410 gluconate Drugs 0.000 description 1
- 230000003450 growing effect Effects 0.000 description 1
- 208000015181 infectious disease Diseases 0.000 description 1
- 239000003999 initiator Substances 0.000 description 1
- 244000000056 intracellular parasite Species 0.000 description 1
- 230000000670 limiting effect Effects 0.000 description 1
- 231100000053 low toxicity Toxicity 0.000 description 1
- 239000006166 lysate Substances 0.000 description 1
- 238000004519 manufacturing process Methods 0.000 description 1
- 239000003550 marker Substances 0.000 description 1
- 102000006240 membrane receptors Human genes 0.000 description 1
- 108020004999 messenger RNA Proteins 0.000 description 1
- 235000006109 methionine Nutrition 0.000 description 1
- 125000001360 methionine group Chemical group N[C@@H](CCSC)C(=O)* 0.000 description 1
- 150000002742 methionines Chemical class 0.000 description 1
- 239000000203 mixture Substances 0.000 description 1
- 244000052769 pathogen Species 0.000 description 1
- 230000001717 pathogenic effect Effects 0.000 description 1
- 239000010452 phosphate Substances 0.000 description 1
- 229920003023 plastic Polymers 0.000 description 1
- 125000002924 primary amino group Chemical group [H]N([H])* 0.000 description 1
- 238000001243 protein synthesis Methods 0.000 description 1
- MCJGNVYPOGVAJF-UHFFFAOYSA-N quinolin-8-ol Chemical compound C1=CN=C2C(O)=CC=CC2=C1 MCJGNVYPOGVAJF-UHFFFAOYSA-N 0.000 description 1
- 230000010837 receptor-mediated endocytosis Effects 0.000 description 1
- 230000004044 response Effects 0.000 description 1
- 210000001995 reticulocyte Anatomy 0.000 description 1
- 210000003660 reticulum Anatomy 0.000 description 1
- 239000011780 sodium chloride Substances 0.000 description 1
- 239000006228 supernatant Substances 0.000 description 1
- 238000012360 testing method Methods 0.000 description 1
- 231100000331 toxic Toxicity 0.000 description 1
- 230000002588 toxic effect Effects 0.000 description 1
- 230000001960 triggered effect Effects 0.000 description 1
- 239000013598 vector Substances 0.000 description 1
- 230000003612 virological effect Effects 0.000 description 1
- 230000001018 virulence Effects 0.000 description 1
Classifications
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
- C12N15/09—Recombinant DNA-technology
- C12N15/11—DNA or RNA fragments; Modified forms thereof; Non-coding nucleic acids having a biological activity
- C12N15/62—DNA sequences coding for fusion proteins
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
- A61K47/51—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
- A61K47/62—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being a protein, peptide or polyamino acid
- A61K47/64—Drug-peptide, drug-protein or drug-polyamino acid conjugates, i.e. the modifying agent being a peptide, protein or polyamino acid which is covalently bonded or complexed to a therapeutically active agent
- A61K47/6415—Toxins or lectins, e.g. clostridial toxins or Pseudomonas exotoxins
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
- A61K47/51—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
- A61K47/62—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being a protein, peptide or polyamino acid
- A61K47/64—Drug-peptide, drug-protein or drug-polyamino acid conjugates, i.e. the modifying agent being a peptide, protein or polyamino acid which is covalently bonded or complexed to a therapeutically active agent
- A61K47/646—Drug-peptide, drug-protein or drug-polyamino acid conjugates, i.e. the modifying agent being a peptide, protein or polyamino acid which is covalently bonded or complexed to a therapeutically active agent the entire peptide or protein drug conjugate elicits an immune response, e.g. conjugate vaccines
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
- A61P31/04—Antibacterial agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
- A61P31/12—Antivirals
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- C07K14/195—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from bacteria
- C07K14/34—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from bacteria from Corynebacterium (G)
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2319/00—Fusion polypeptide
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2319/00—Fusion polypeptide
- C07K2319/01—Fusion polypeptide containing a localisation/targetting motif
- C07K2319/02—Fusion polypeptide containing a localisation/targetting motif containing a signal sequence
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2319/00—Fusion polypeptide
- C07K2319/55—Fusion polypeptide containing a fusion with a toxin, e.g. diphteria toxin
Landscapes
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Engineering & Computer Science (AREA)
- General Health & Medical Sciences (AREA)
- Organic Chemistry (AREA)
- Medicinal Chemistry (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Animal Behavior & Ethology (AREA)
- Pharmacology & Pharmacy (AREA)
- Public Health (AREA)
- Veterinary Medicine (AREA)
- Molecular Biology (AREA)
- Genetics & Genomics (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- Chemical Kinetics & Catalysis (AREA)
- General Chemical & Material Sciences (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Biomedical Technology (AREA)
- Oncology (AREA)
- Communicable Diseases (AREA)
- General Engineering & Computer Science (AREA)
- Biochemistry (AREA)
- Virology (AREA)
- Epidemiology (AREA)
- Biophysics (AREA)
- Biotechnology (AREA)
- Wood Science & Technology (AREA)
- Zoology (AREA)
- Toxicology (AREA)
- Microbiology (AREA)
- Physics & Mathematics (AREA)
- Plant Pathology (AREA)
- Gastroenterology & Hepatology (AREA)
- Immunology (AREA)
- Peptides Or Proteins (AREA)
- Preparation Of Compounds By Using Micro-Organisms (AREA)
- Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
Applications Claiming Priority (2)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| NO902871A NO175188C (no) | 1990-06-27 | 1990-06-27 | Fremgangsmåte for fremstilling av et peptidkonjugat med evne til å trenge inn i cellecytosol |
| NO902871 | 1990-06-27 |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| CA2086342A1 true CA2086342A1 (fr) | 1991-12-28 |
Family
ID=19893304
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| CA002086342A Abandoned CA2086342A1 (fr) | 1990-06-27 | 1991-06-26 | Methode permettant d'introduire un peptide dans un cytosol |
Country Status (8)
| Country | Link |
|---|---|
| EP (1) | EP0542756A1 (fr) |
| JP (1) | JPH06503552A (fr) |
| CA (1) | CA2086342A1 (fr) |
| FI (1) | FI925869A (fr) |
| HU (1) | HUT63061A (fr) |
| LT (1) | LTIP835A (fr) |
| NO (1) | NO175188C (fr) |
| WO (1) | WO1992000099A1 (fr) |
Families Citing this family (13)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US6043057A (en) * | 1988-09-16 | 2000-03-28 | Vitec Aktiebolag | Recombinant systems for expression of the cholera B-sub-unit with the aid of foreign promoters and/or leader peptides |
| US5314813A (en) * | 1992-02-19 | 1994-05-24 | Scripps Research Institute | Drosophila cell lines expressing genes encoding MHC class I antigens and B2-microglobulin and capable of assembling empty complexes and methods of making said cell lines |
| US5935580A (en) * | 1992-04-21 | 1999-08-10 | Institut Pasteur | Recombinant mutants for inducing specific immune responses |
| PT637335E (pt) * | 1992-04-21 | 2007-10-31 | Pasteur Institut | Mutantes recombinantes para induzir respostas imunitárias específicas |
| US6455673B1 (en) | 1994-06-08 | 2002-09-24 | President And Fellows Of Harvard College | Multi-mutant diphtheria toxin vaccines |
| US20030165543A1 (en) * | 2000-01-27 | 2003-09-04 | Langridge William H.R. | Transgenic plant-based vaccines |
| US6777546B2 (en) | 1997-10-07 | 2004-08-17 | Loma Linda University | Methods and substances for preventing and treating autoimmune disease |
| US7422747B2 (en) | 1997-10-07 | 2008-09-09 | Loma Linda University | Transgenic plant-based vaccines |
| US6004815A (en) * | 1998-08-13 | 1999-12-21 | The Regents Of The University Of California | Bacteria expressing nonsecreted cytolysin as intracellular microbial delivery vehicles to eukaryotic cells |
| DE60042687D1 (de) | 2000-09-15 | 2009-09-17 | Pasteur Institut | Proteinhaltigen Vektoren zur Einführung von Moleküle in CD11b exprimirende Zellen |
| GB0524408D0 (en) * | 2005-11-30 | 2006-01-11 | Glaxosmithkline Biolog Sa | Vaccines |
| US11965009B2 (en) | 2016-03-10 | 2024-04-23 | The Johns Hopkins University | Methods of producing aggregate-free monomeric diphtheria toxin fusion proteins and therapeutic uses |
| CA3017143A1 (fr) * | 2016-03-10 | 2017-09-14 | The Johns Hopkins University | Procedes de production de proteines de fusion de toxine diphterique monomere sans agregat et utilisations therapeutiques |
Family Cites Families (6)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| EP0108146B1 (fr) * | 1982-05-12 | 1987-01-28 | The President And Fellows Of Harvard College | Gènes de fusion codant des protéines hybrides, vecteurs de clonage les contenant et leur emploi |
| FR2532850B1 (fr) * | 1982-09-15 | 1985-12-20 | Pasteur Institut | Conjugues immunogenes entre un haptene et une molecule porteuse derivee d'une toxine, les vaccins les composant et procede pour leur obtention |
| US4808700A (en) * | 1984-07-09 | 1989-02-28 | Praxis Biologics, Inc. | Immunogenic conjugates of non-toxic E. coli LT-B enterotoxin subunit and capsular polymers |
| IL89504A0 (en) * | 1988-03-08 | 1989-09-10 | Univ Wyoming | Diphtheria toxin derivative,process for the preparation thereof and pharmaceutical composition containing the same |
| FR2636842B1 (fr) * | 1988-09-27 | 1994-06-10 | Liege Universite Etat | Proteine de fusion d'une sequence derivee de la sous-unite b de la toxine cholerique et d'un antigene heterologue doue de proprietes immunogenes, compositions de vaccins les contenant et acides nucleiques recombinants contenant une sequence de nucleotides codant pour ladite proteine de fusion |
| WO1991009871A1 (fr) * | 1989-12-22 | 1991-07-11 | Seragen Incorporated | Molecules hybrides presentant une region de translocation et une region de liaison cellulaire |
-
1990
- 1990-06-27 NO NO902871A patent/NO175188C/no unknown
-
1991
- 1991-06-26 CA CA002086342A patent/CA2086342A1/fr not_active Abandoned
- 1991-06-26 JP JP3510777A patent/JPH06503552A/ja active Pending
- 1991-06-26 HU HU924125A patent/HUT63061A/hu unknown
- 1991-06-26 EP EP91911315A patent/EP0542756A1/fr not_active Withdrawn
- 1991-06-26 WO PCT/NO1991/000093 patent/WO1992000099A1/fr not_active Application Discontinuation
-
1992
- 1992-12-23 FI FI925869A patent/FI925869A/fi unknown
-
1993
- 1993-08-03 LT LTIP835A patent/LTIP835A/xx unknown
Also Published As
| Publication number | Publication date |
|---|---|
| HU9204125D0 (en) | 1993-04-28 |
| LTIP835A (en) | 1995-02-27 |
| JPH06503552A (ja) | 1994-04-21 |
| FI925869A0 (fi) | 1992-12-23 |
| NO902871D0 (no) | 1990-06-27 |
| NO175188C (no) | 1994-09-14 |
| WO1992000099A1 (fr) | 1992-01-09 |
| NO902871L (no) | 1991-12-30 |
| EP0542756A1 (fr) | 1993-05-26 |
| HUT63061A (en) | 1993-07-28 |
| NO175188B (fr) | 1994-06-06 |
| FI925869A (fi) | 1992-12-23 |
| AU653158B2 (en) | 1994-09-22 |
| AU8000191A (en) | 1992-01-23 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| CA2691539C (fr) | Toxines modifiees | |
| Antoine et al. | Roles of the disulfide bond and the carboxy-terminal region of the S1 subunit in the assembly and biosynthesis of pertussis toxin | |
| ES2290950T3 (es) | Mutantes recombinantes para inducir respuestas inmunitarias especificas. | |
| Stenmark et al. | Peptides fused to the amino-terminal end of diphtheria toxin are translocated to the cytosol. | |
| JP3755773B2 (ja) | 変異型ｒドメインを有するジフテリア毒素ワクチン | |
| Collier | Understanding the mode of action of diphtheria toxin: a perspective on progress during the 20th century | |
| US5601827A (en) | Diphtheria toxin vaccines | |
| US6086900A (en) | Methods and compositions for using membrane-penetrating proteins to carry materials across cell membranes | |
| CA2086342A1 (fr) | Methode permettant d'introduire un peptide dans un cytosol | |
| JPH04501051A (ja) | 組換え型ｄｎａ由来ボルデテラ毒素サブユニット類似体 | |
| Madshus et al. | Membrane translocation of diphtheria toxin carrying passenger protein domains | |
| De Haan et al. | Enhanced delivery of exogenous peptides into the class I antigen processing and presentation pathway | |
| US6545126B1 (en) | Chimeric toxins | |
| Nicholls et al. | The structure of diphtheria toxin as a guide to rational design | |
| US8425917B2 (en) | Mutant forms of EtxB and CtxB and their use as carriers | |
| JP2004531230A (ja) | Ｇｂ３レセプター発現細胞を標的とする分子の一般担体 | |
| Madshus et al. | Entry of ADP-ribosylating toxins into cells | |
| Idziorek et al. | Low pH-induced changes in Pseudomonas exotoxin and its domains: increased binding of Triton X-114 | |
| CA2069106A1 (fr) | Proteines chimeriques | |
| AU633842B2 (en) | Recombinant systems for expression of cholera b-subunit with the aid of foreign promoters and/or leader peptides | |
| AU653158C (en) | Method of introducing a peptide into the cytosol | |
| US5834246A (en) | Recombinant systems for expression of cholera B-subunit with the aid of foreign promoters and/or leader peptides | |
| US6043057A (en) | Recombinant systems for expression of the cholera B-sub-unit with the aid of foreign promoters and/or leader peptides | |
| US6803358B1 (en) | Ricin-like toxin variants for treatment of cancer, viral or parasitic infections | |
| Stenmark et al. | Elimination of the disulphide bridge in fragment B of diphtheria toxin: effect on membrane insertion, channel formation, and ATP binding |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| FZDE | Discontinued |